Site-specific PEGylated exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects

Bioconjugate Chemistry

Volumn 23, Issue 11, 2012, Pages 2214-2220

  Kim, Tae Hyung ^a   Jiang, Hai Hua ^a   Lim, Sung Mook ^a   Youn, Yu Seok ^a   Choi, Ki Young ^b   Lee, Seulki ^b   Chen, Xiaoyuan ^b   Byun, Youngro ^c   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; DRUG PRODUCTS; MASS SPECTROMETRY; MOLECULAR WEIGHT;

ANTIDIABETIC; COUPLING REACTION; HIGH MOLECULAR WEIGHT; HIGHER YIELD; PEGYLATED; PEGYLATION; RECEPTOR BINDING; SITE-SPECIFIC; STERIC HINDRANCES; THERAPEUTIC EFFECTS;

AMINO ACIDS;

AMINE; CYSTEINE; EXENDIN 4; PEGYLATED EXENDIN 4 ANALOUGE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG STRUCTURE; IN VITRO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

EID: 84869748023     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300265n     Document Type: Article

References (25)

1. Katre, N. V. (1993) The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential Adv. Drug Delivery Rev. 10, 91-114
2. Veronese, F. M., Monfardini, C., Caliceti, P., Schiavon, O., Scrawen, D., and Beer, D. (1996) Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol) J. Controlled Release 40, 199-209
3. Kang, J. S., Deluca, P. P., and Lee, K. C. (2009) Emerging PEGylated drugs Expert Opin. Emerg. Drugs 14, 363-380
4. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., Berthold, W., and Graves, M. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjugate Chem. 12, 195-202
5. Parkinson, C., Scarlett, J. A., and Trainer, P. J. (2003) Pegvisomant in the treatment of acromegaly Adv. Drug Delivery Rev. 55, 1303-1314
6. Edwards, C. K., 3rd, Martin, S. W., Seely, J., Kinstler, O., Buckel, S., Bendele, A. M., Ellen Cosenza, M., Feige, U., and Kohno, T. (2003) Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases Adv. Drug Delivery Rev. 55, 1315-1336
7. Whelan, J. (2005) Beyond PEGylation Drug Discovery Today 10, 301
8. Youn, Y. S., Na, D. H., Yoo, S. D., Song, S. C., and Lee, K.C. (2005) Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential Int. J. Biochem. Cell Biol. 37, 1525-1533
9. Deiters, A., Cropp, T. A., Summerer, D., Mukherji, M., and Schultz, P. G. (2004) Site-specific PEGylation of proteins containing unnatural amino acids Bioorg. Med. Chem. Lett. 14, 5743-5745
10. Youn, Y. S. and Lee, K. C. (2007) Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12) Bioconjugate Chem 18, 500-506
11. Youn, Y. S., Na, D. H., and Lee, K. C. (2007) High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation J. Controlled Release 117, 371-379
12. Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., and Baron, A. D. (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J. Clin. Endocrinol. Metab. 88, 3082-3089
13. Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G., Greig, N. H., and Egan, J. M. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141, 1936-1941
14. Nielsen, L. L., Young, A. A., and Parkes, D. G. (2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul. Pept. 117, 77-88
15. Drucker, D. J. and Nauck, M. A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368, 1696-1705
16. Simonsen, L., Holst, J. J., and Deacon, C. F. (2006) Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs Diabetologia 49, 706-712
17. Jin, C. H., Chae, S. Y., Son, S., Kim, T. H., Um, K. A., Youn, Y. S., Lee, S., and Lee, K. C. (2009) A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice J. Controlled Release 133, 172-177
18. Chae, S. Y., Jin, C. H., Shin, J. H., Son, S., Kim, T. H., Lee, S., Youn, Y. S., Byun, Y., Lee, M. S., and Lee, K. C. (2010) Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J. Controlled Release 142, 206-213
19. Son, S., Chae, S. Y., Kim, C. W., Choi, Y. G., Jung, S. Y., Lee, S., and Lee, K. C. (2009) Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives J. Med. Chem. 52, 6889-6896
20. Kim, T. H., Jiang, H. H., Lee, S., Youn, Y. S., Park, C. W., Byun, Y., Chen, X., and Lee, K. C. (2011) Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics Bioconjugate Chem. 22, 625-632
21. Kim, T. H., Youn, Y. S., Jiang, H. H., Lee, S., Chen, X., and Lee, K. C. (2011) PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjugate Chem. 22, 1631-1637
22. Chae, S. Y., Kim, T. H., Park, K., Jin, C. H., Son, S., Lee, S., Youn, Y. S., Kim, K., Jo, D. G., Kwon, I. C., Chen, X., and Lee, K. C. (2010) Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand Mol. Cancer Ther. 9, 1719-1729
23. Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobayashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., and Mayumi, T. (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity Nat. Biotechnol. 21, 546-552
24. Moreadith, R. W. and Collen, D. (2003) Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction Adv. Drug Delivery Rev. 55, 1337-1345
25. Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation Bioconjugate Chem. 16, 200-207